New York, June 16, 2026, 07:02 (ET)
- IM Cannabis ended Monday up nearly 12% and kept climbing early Tuesday in premarket.
- No fresh company announcements over the past 24–48 hours appear to account for the move.
- Investors are watching the company’s resale-registration filing and the Nasdaq bid-price deadline.
IM Cannabis Corp. shares are trading heavy again. IMCC closed at $0.2610 on June 15, up 12.31% on Nasdaq, and was last seen at $0.3491 in the premarket at 6:43 a.m. ET on June 16, according to StockAnalysis market data StockAnalysis. The stock is moving without any fresh company updates. The company’s investor-relations site and SEC filings show the last events were a June 9 Form F-3 resale registration and a related 6-K and the June 3 financing filing. Nothing new has hit in the past day or so IM Cannabis Corp..
IM Cannabis stock climbed, but the action looks like penny stock trading. Finviz reported 100.7 million shares traded versus a 2.30 million average. Shares are still down 89% over the last year and trade 93% below the 52-week high Finviz. These volume spikes can launch a small-cap when traders pile in, though gains may vanish just as quickly if buyers pull out.
IM Cannabis’s dilution risk is back on the table. The company said June 9 it’s filed a Form F-3 resale registration statement. If the registration becomes effective, holders on the form can sell shares in the market. The filing covers 17,276,931 common shares tied to old convertible notes and warrants. IM Cannabis doesn’t get any of the proceeds as those holders sell out PR Newswire. On June 3, the company also raised US$225,000 with a convertible note, conversion set at the lower of US$0.288 per share or 90% of the lowest daily volume-weighted average price, but not lower than US$0.0576. VWAP refers to the average price paid by volume over a given period PR Newswire.
The rally isn’t a clear sign for bulls. In its SEC filing, the company said converting fully and exercising the warrants could send outstanding shares up from 9,016,539 to 36,632,436, a jump of about 306%. The company also warned the stock might come under pressure from resales or just the worry that resales could happen. IM Cannabis still trades below Nasdaq’s US$1.00 minimum bid price and is staring down an October 6, 2026 deadline to regain compliance by trading back above that mark for 10 straight business days.
IM Cannabis posted 2025 revenue of C$54.73 million, with medical cannabis operations in Israel and Germany. The company continues to sell under its IMC, BLKMT and LOT420 brand names StockAnalysis. On the downside, revenue slipped to C$8.7 million in the first quarter of 2026, and IM Cannabis booked a net loss of C$2.5 million. The company’s balance sheet is supported by small convertible financings, which could mean more shares ahead IM Cannabis Corp..
SEC decision on the resale registration is up next, with the focus also on what IM Cannabis does about its Nasdaq bid-price issue before the October deadline. At this stage, IM Cannabis is risky rather than clearly attractive. The low share price and high trading volume could appeal to speculators, but dilution risk, continued losses, and Nasdaq compliance problems make it hard to get comfortable with the fundamentals.
